Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic viral hepatitis C: management update.

K S Gutfreund1, V G Bain

  • 1Department of Medicine, University of Alberta, Edmonton. klaus.gutfreund@ualberta.ca

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|April 6, 2000
PubMed
Summary

Combination therapy with interferon and ribavirin improves sustained virological response rates for chronic hepatitis C. Careful patient selection and monitoring are crucial due to potential side effects, highlighting the need for new treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis.

International journal of immunogenetics·2015
Same author

The Pekin duck IL-10R2 common chain: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis.

International journal of immunogenetics·2013
Same author

cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis of the Pekin duck interleukin-10 receptor 1.

International journal of immunogenetics·2011
Same author

Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival.

Alimentary pharmacology & therapeutics·2009
Same author

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie·2009
Same author

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.

Alimentary pharmacology & therapeutics·2008

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic viral hepatitis C management is rapidly evolving.
  • Interferon monotherapy previously offered limited sustained virological response (SVR) rates of 15%.
  • Hepatitis C virus (HCV) infection remains a significant global health concern.

Purpose of the Study:

  • To evaluate the efficacy and challenges of combination therapy for chronic hepatitis C.
  • To discuss the implications of new treatment guidelines and the need for specialized patient management.
  • To identify the limitations of current therapies and the necessity for novel antiviral agents.

Main Methods:

  • Review of current treatment strategies for chronic hepatitis C.
  • Analysis of sustained virological response rates for monotherapy versus combination therapy.

Related Experiment Videos

  • Assessment of side effect profiles and patient monitoring requirements for combination treatment.

    • Main Results:

    • Combination therapy with interferon alpha-2b and ribavirin significantly increases SVR rates to 40% (treatment-naive) and 50% (relapsed patients).
    • Combination treatment is now approved in Canada but requires specialized expertise for patient selection and monitoring.
    • Significant side effects necessitate careful monitoring and can lead to treatment discontinuation.

    Conclusions:

    • Combination therapy represents a significant advancement in chronic hepatitis C management, offering higher response rates.
    • Effective patient selection and vigilant monitoring are essential to mitigate adverse events associated with combination treatment.
    • The persistent challenge of low SVR rates in certain patient groups, particularly those with HCV genotype 1, underscores the urgent need for the development of novel antiviral medications targeting the HCV genome.